Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk

Akira Matsunobu, Reiko Imai, Tadashi Kamada, Takeshi Imaizumi, Hiroshi Tsuji, Hirohiko Tsujii, Yoshiyuki Shioyama, Hiroshi Honda, Shin Ichiro Tatezaki

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

BACKGROUND: The authors summarized the outcomes of patients with unresectable osteosarcoma of the trunk who received carbon ion radiotherapy (CIRT). METHODS: The authors performed a retrospective analysis of 78 patients who had medically inoperable osteosarcoma of the trunk and received treatment with CIRT between 1996 and 2009. Tumor sites included the pelvis in 61 patients, the spine and paraspinal region in 15 patients, and other sites in 2 patients. The median applied CIRT dose was 70.4 Gray equivalent (GyE) in a total of 16 fixed fractions over 4 weeks. RESULTS: The minimum duration of follow-up for survivors was 14 months. Forty-eight patients remained alive. The 5-year overall survival rate was 33%, and the local control rate was 62%. Thirty-eight patients who had a clinical target volume <500 cm3 had a 5-year overall survival rate of 46% and a 5-year local control rate of 88%. Except for 3 patients who experienced severe skin/soft tissue complications requiring skin grafts, no other severe toxicities were observed. Of 9 patients who were continuously disease free for >5 years, 8 were able to walk with or without the help of a cane, and 6 were free from pain killers. CONCLUSIONS: CIRT appeared to be a safe and effective modality for the management of unresectable osteosarcoma of the trunk, providing good local control and offering a survival advantage and good long-term functional results without unacceptable morbidity. Cancer 2012.

Original languageEnglish
Pages (from-to)4555-4563
Number of pages9
JournalCancer
Volume118
Issue number18
DOIs
Publication statusPublished - Sep 15 2012

Fingerprint

Heavy Ion Radiotherapy
Osteosarcoma
Canes
Pelvis
Survivors
Neoplasms
Spine
Survival Rate
Morbidity
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Matsunobu, A., Imai, R., Kamada, T., Imaizumi, T., Tsuji, H., Tsujii, H., ... Tatezaki, S. I. (2012). Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer, 118(18), 4555-4563. https://doi.org/10.1002/cncr.27451

Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. / Matsunobu, Akira; Imai, Reiko; Kamada, Tadashi; Imaizumi, Takeshi; Tsuji, Hiroshi; Tsujii, Hirohiko; Shioyama, Yoshiyuki; Honda, Hiroshi; Tatezaki, Shin Ichiro.

In: Cancer, Vol. 118, No. 18, 15.09.2012, p. 4555-4563.

Research output: Contribution to journalArticle

Matsunobu, A, Imai, R, Kamada, T, Imaizumi, T, Tsuji, H, Tsujii, H, Shioyama, Y, Honda, H & Tatezaki, SI 2012, 'Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk', Cancer, vol. 118, no. 18, pp. 4555-4563. https://doi.org/10.1002/cncr.27451
Matsunobu A, Imai R, Kamada T, Imaizumi T, Tsuji H, Tsujii H et al. Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer. 2012 Sep 15;118(18):4555-4563. https://doi.org/10.1002/cncr.27451
Matsunobu, Akira ; Imai, Reiko ; Kamada, Tadashi ; Imaizumi, Takeshi ; Tsuji, Hiroshi ; Tsujii, Hirohiko ; Shioyama, Yoshiyuki ; Honda, Hiroshi ; Tatezaki, Shin Ichiro. / Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. In: Cancer. 2012 ; Vol. 118, No. 18. pp. 4555-4563.
@article{fe4c74707d034002a5cdb8462fdbbadc,
title = "Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk",
abstract = "BACKGROUND: The authors summarized the outcomes of patients with unresectable osteosarcoma of the trunk who received carbon ion radiotherapy (CIRT). METHODS: The authors performed a retrospective analysis of 78 patients who had medically inoperable osteosarcoma of the trunk and received treatment with CIRT between 1996 and 2009. Tumor sites included the pelvis in 61 patients, the spine and paraspinal region in 15 patients, and other sites in 2 patients. The median applied CIRT dose was 70.4 Gray equivalent (GyE) in a total of 16 fixed fractions over 4 weeks. RESULTS: The minimum duration of follow-up for survivors was 14 months. Forty-eight patients remained alive. The 5-year overall survival rate was 33{\%}, and the local control rate was 62{\%}. Thirty-eight patients who had a clinical target volume <500 cm3 had a 5-year overall survival rate of 46{\%} and a 5-year local control rate of 88{\%}. Except for 3 patients who experienced severe skin/soft tissue complications requiring skin grafts, no other severe toxicities were observed. Of 9 patients who were continuously disease free for >5 years, 8 were able to walk with or without the help of a cane, and 6 were free from pain killers. CONCLUSIONS: CIRT appeared to be a safe and effective modality for the management of unresectable osteosarcoma of the trunk, providing good local control and offering a survival advantage and good long-term functional results without unacceptable morbidity. Cancer 2012.",
author = "Akira Matsunobu and Reiko Imai and Tadashi Kamada and Takeshi Imaizumi and Hiroshi Tsuji and Hirohiko Tsujii and Yoshiyuki Shioyama and Hiroshi Honda and Tatezaki, {Shin Ichiro}",
year = "2012",
month = "9",
day = "15",
doi = "10.1002/cncr.27451",
language = "English",
volume = "118",
pages = "4555--4563",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "18",

}

TY - JOUR

T1 - Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk

AU - Matsunobu, Akira

AU - Imai, Reiko

AU - Kamada, Tadashi

AU - Imaizumi, Takeshi

AU - Tsuji, Hiroshi

AU - Tsujii, Hirohiko

AU - Shioyama, Yoshiyuki

AU - Honda, Hiroshi

AU - Tatezaki, Shin Ichiro

PY - 2012/9/15

Y1 - 2012/9/15

N2 - BACKGROUND: The authors summarized the outcomes of patients with unresectable osteosarcoma of the trunk who received carbon ion radiotherapy (CIRT). METHODS: The authors performed a retrospective analysis of 78 patients who had medically inoperable osteosarcoma of the trunk and received treatment with CIRT between 1996 and 2009. Tumor sites included the pelvis in 61 patients, the spine and paraspinal region in 15 patients, and other sites in 2 patients. The median applied CIRT dose was 70.4 Gray equivalent (GyE) in a total of 16 fixed fractions over 4 weeks. RESULTS: The minimum duration of follow-up for survivors was 14 months. Forty-eight patients remained alive. The 5-year overall survival rate was 33%, and the local control rate was 62%. Thirty-eight patients who had a clinical target volume <500 cm3 had a 5-year overall survival rate of 46% and a 5-year local control rate of 88%. Except for 3 patients who experienced severe skin/soft tissue complications requiring skin grafts, no other severe toxicities were observed. Of 9 patients who were continuously disease free for >5 years, 8 were able to walk with or without the help of a cane, and 6 were free from pain killers. CONCLUSIONS: CIRT appeared to be a safe and effective modality for the management of unresectable osteosarcoma of the trunk, providing good local control and offering a survival advantage and good long-term functional results without unacceptable morbidity. Cancer 2012.

AB - BACKGROUND: The authors summarized the outcomes of patients with unresectable osteosarcoma of the trunk who received carbon ion radiotherapy (CIRT). METHODS: The authors performed a retrospective analysis of 78 patients who had medically inoperable osteosarcoma of the trunk and received treatment with CIRT between 1996 and 2009. Tumor sites included the pelvis in 61 patients, the spine and paraspinal region in 15 patients, and other sites in 2 patients. The median applied CIRT dose was 70.4 Gray equivalent (GyE) in a total of 16 fixed fractions over 4 weeks. RESULTS: The minimum duration of follow-up for survivors was 14 months. Forty-eight patients remained alive. The 5-year overall survival rate was 33%, and the local control rate was 62%. Thirty-eight patients who had a clinical target volume <500 cm3 had a 5-year overall survival rate of 46% and a 5-year local control rate of 88%. Except for 3 patients who experienced severe skin/soft tissue complications requiring skin grafts, no other severe toxicities were observed. Of 9 patients who were continuously disease free for >5 years, 8 were able to walk with or without the help of a cane, and 6 were free from pain killers. CONCLUSIONS: CIRT appeared to be a safe and effective modality for the management of unresectable osteosarcoma of the trunk, providing good local control and offering a survival advantage and good long-term functional results without unacceptable morbidity. Cancer 2012.

UR - http://www.scopus.com/inward/record.url?scp=84865959716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865959716&partnerID=8YFLogxK

U2 - 10.1002/cncr.27451

DO - 10.1002/cncr.27451

M3 - Article

C2 - 22359113

AN - SCOPUS:84865959716

VL - 118

SP - 4555

EP - 4563

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 18

ER -